Logo image of KLTO

KLOTHO NEUROSCIENCES INC (KLTO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KLTO - US49876K1034 - Common Stock

0.3248 USD
+0 (+1.06%)
Last: 1/6/2026, 12:59:48 PM
Fundamental Rating

2

Taking everything into account, KLTO scores 2 out of 10 in our fundamental rating. KLTO was compared to 530 industry peers in the Biotechnology industry. While KLTO has a great health rating, there are worries on its profitability. KLTO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KLTO had negative earnings in the past year.
In the past year KLTO has reported a negative cash flow from operations.
KLTO Yearly Net Income VS EBIT VS OCF VS FCFKLTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -2M -4M -6M

1.2 Ratios

KLTO has a Return On Assets of -112.08%. This is in the lower half of the industry: KLTO underperforms 78.11% of its industry peers.
KLTO has a Return On Equity of -113.73%. This is comparable to the rest of the industry: KLTO outperforms 42.45% of its industry peers.
Industry RankSector Rank
ROA -112.08%
ROE -113.73%
ROIC N/A
ROA(3y)-80.77%
ROA(5y)N/A
ROE(3y)-168.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KLTO Yearly ROA, ROE, ROICKLTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

KLTO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLTO Yearly Profit, Operating, Gross MarginsKLTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for KLTO has been increased compared to 1 year ago.
Compared to 1 year ago, KLTO has a worse debt to assets ratio.
KLTO Yearly Shares OutstandingKLTO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
KLTO Yearly Total Debt VS Total AssetsKLTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 91.69 indicates that KLTO is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 91.69, KLTO belongs to the top of the industry, outperforming 98.87% of the companies in the same industry.
KLTO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 91.69
ROIC/WACCN/A
WACCN/A
KLTO Yearly LT Debt VS Equity VS FCFKLTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 83.68 indicates that KLTO has no problem at all paying its short term obligations.
KLTO has a Current ratio of 83.68. This is amongst the best in the industry. KLTO outperforms 99.81% of its industry peers.
A Quick Ratio of 83.68 indicates that KLTO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 83.68, KLTO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 83.68
Quick Ratio 83.68
KLTO Yearly Current Assets VS Current LiabilitesKLTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for KLTO have decreased strongly by -38.42% in the last year.
EPS 1Y (TTM)-38.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KLTO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLTO Price Earnings VS Forward Price EarningsKLTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KLTO Per share dataKLTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KLTO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

KLOTHO NEUROSCIENCES INC

NASDAQ:KLTO (1/6/2026, 12:59:48 PM)

0.3248

+0 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-31 2026-03-31
Inst Owners2.62%
Inst Owner Change0%
Ins Owners8.35%
Ins Owner Change21.55%
Market Cap23.56M
Revenue(TTM)N/A
Net Income(TTM)-11.29M
AnalystsN/A
Price TargetN/A
Short Float %0.44%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.37
P/tB 3.09
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS0.14
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -112.08%
ROE -113.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-80.77%
ROA(5y)N/A
ROE(3y)-168.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 83.68
Quick Ratio 83.68
Altman-Z 91.69
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.53%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-79.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-412.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-412.45%
OCF growth 3YN/A
OCF growth 5YN/A

KLOTHO NEUROSCIENCES INC / KLTO FAQ

What is the ChartMill fundamental rating of KLOTHO NEUROSCIENCES INC (KLTO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KLTO.


What is the valuation status for KLTO stock?

ChartMill assigns a valuation rating of 0 / 10 to KLOTHO NEUROSCIENCES INC (KLTO). This can be considered as Overvalued.


What is the profitability of KLTO stock?

KLOTHO NEUROSCIENCES INC (KLTO) has a profitability rating of 0 / 10.


What is the financial health of KLOTHO NEUROSCIENCES INC (KLTO) stock?

The financial health rating of KLOTHO NEUROSCIENCES INC (KLTO) is 8 / 10.